Stay updated on PI3Kinase Inhibition and Nivolumab in Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the PI3Kinase Inhibition and Nivolumab in Solid Tumors Clinical Trial page.

Latest updates to the PI3Kinase Inhibition and Nivolumab in Solid Tumors Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedAdded Revision: v3.4.2. Removed the government funding lapse notice and Revision: v3.4.1 banner.SummaryDifference0.4%

- Check21 days agoChange DetectedAdded a banner about government funding status and updated the page revision to v3.4.1, replacing the previous v3.4.0 revision note.SummaryDifference0.4%

- Check28 days agoChange DetectedThe page now includes a glossary control and updates several footer/metadata items, including Last Update Submitted that Met QC Criteria, Last Update Posted, capitalization changes to No FEAR Act Data, and the revision noted as v3.4.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check42 days agoChange DetectedThe page now displays Revision: v3.3.4, replacing the previous Revision: v3.3.3.SummaryDifference0.0%

- Check64 days agoChange DetectedThe page now includes a dedicated Locations section identifying Maryland (Baltimore, MD) as the study site, clarifying where the trial is conducted. It also shows the removal of the HHS Vulnerability Disclosure link and the prior Maryland Locations entry, with the revision updated to v3.3.3.SummaryDifference0.2%

- Check85 days agoChange DetectedThe page shows an updated revision tag from v3.3.1 to v3.3.2, a minor metadata update with no change to the study details. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

Stay in the know with updates to PI3Kinase Inhibition and Nivolumab in Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the PI3Kinase Inhibition and Nivolumab in Solid Tumors Clinical Trial page.